Human papillomavirus vaccines: current issues & future

Area of Science:

• Oncology
• Virology
• Vaccinology
• Public Health

Background:

• Cervical cancer, primarily caused by human papillomaviruses (HPVs), is a leading global cause of cancer mortality in women.
• While screening programs are effective in high-resource settings, they are often impractical in developing countries due to cost and complexity.
• Persistent HPV infections, particularly those involving oncogenic HPV types, can progress to cervical cancer.

Purpose of the Study:

• To review the current landscape of prophylactic HPV vaccines and their limitations.
• To highlight the need for broader-spectrum prophylactic and therapeutic HPV vaccines.
• To discuss the potential of novel vaccine strategies for cervical cancer prevention and treatment.

Main Methods:

• Review of existing literature on HPV infections, cervical cancer, and current prophylactic HPV vaccines (Gardasil and Cervarix).
• Analysis of the mechanisms and limitations of L1 virus-like particle (VLP) HPV vaccines.
• Discussion of ongoing research and development in broad-spectrum prophylactic and therapeutic HPV vaccines.

Main Results:

• Current prophylactic HPV vaccines, such as Gardasil and Cervarix, target specific HPV types (e.g., HPV-16, -18) and are type-specific.
• The efficacy of current vaccines is limited by the number of targeted HPV types, necessitating costly cytologic screening.
• Development is underway for multivalent vaccines covering more oncogenic HPV types and therapeutic vaccines for existing lesions.

Conclusions:

• Current HPV vaccines are a promising but not ultimate strategy for cervical cancer prevention.
• There is a critical need for the development of broad-spectrum prophylactic vaccines against all oncogenic HPV types.
• Therapeutic vaccines are essential for clearing existing HPV-related cervical lesions and reducing cancer incidence.